The impact of mergers on pharmaceutical R&D

被引：57
作者：
LaMattina, John L.
机构：
[1] John L. LaMattina is the former President of Pfizer Global Research and Development,
[2] and is currently Senior Partner at Puretech Ventures,undefined
[3] Boston,undefined
[4] Massachusetts 02116,undefined
[5] USA. john.lamattina@comcast.net,undefined
来源：
NATURE REVIEWS DRUG DISCOVERY | 2011年 / 10卷 / 08期
关键词：
D O I：
10.1038/nrd3514
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Mergers and acquisitions in the pharmaceutical industry have substantially reduced the number of major companies over the past 15 years. The short-term business rationale for this extensive consolidation might have been reasonable, but at what cost to research and development productivity? © 2011 Macmillan Publishers Limited. All rights reserved.
引用
收藏
页码：559 / 560
页数：2
相关论文
共 3 条
[1]  
Garnier JP, 2008, HARVARD BUS REV, V86, P68
[2]   Lessons from 60 years of pharmaceutical innovation [J].
Munos, Bernard .
NATURE REVIEWS DRUG DISCOVERY, 2009, 8 (12) :959-968
[3]   How to improve R&D productivity: the pharmaceutical industry's grand challenge [J].
Paul, Steven M. ;
Mytelka, Daniel S. ;
Dunwiddie, Christopher T. ;
Persinger, Charles C. ;
Munos, Bernard H. ;
Lindborg, Stacy R. ;
Schacht, Aaron L. .
NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (03) :203-214
1